Pharma Aids Limited (DSE:PHARMAID)
Bangladesh
· Delayed Price · Currency is BDT 481.30
-7.20 (-1.47%)
At close: May 13, 2025
Pharma Aids Income Statement
Financials in millions BDT. Fiscal year is July - June.
Millions BDT. Fiscal year is Jul - Jun.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2015 - 2019 |
| Revenue | 421.23 | 308.49 | 323.05 | 280.29 | 269.57 | Upgrade
|
| Revenue Growth (YoY) | 36.55% | -4.50% | 15.25% | 3.98% | 8.24% | Upgrade
|
| Cost of Revenue | 291.88 | 257.2 | 219.58 | 174.95 | 163.13 | Upgrade
|
| Gross Profit | 129.36 | 51.29 | 103.47 | 105.34 | 106.44 | Upgrade
|
| Selling, General & Admin | 44.03 | 37.32 | 45.63 | 38.17 | 33.55 | Upgrade
|
| Other Operating Expenses | 0.07 | 2.21 | 1.94 | 0.07 | 0.12 | Upgrade
|
| Operating Expenses | 44.99 | 40.63 | 49.45 | 39.02 | 34.61 | Upgrade
|
| Operating Income | 84.36 | 10.66 | 54.02 | 66.33 | 71.84 | Upgrade
|
| Interest Expense | -0.26 | -0.24 | -0.38 | -0.9 | -0.89 | Upgrade
|
| Interest & Investment Income | 0.62 | - | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -0.16 | -0.13 | -0.09 | -0.07 | -0.14 | Upgrade
|
| EBT Excluding Unusual Items | 84.56 | 10.3 | 53.54 | 65.35 | 70.81 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | -0.84 | Upgrade
|
| Pretax Income | 84.56 | 10.3 | 53.54 | 65.35 | 69.97 | Upgrade
|
| Income Tax Expense | 23.38 | 16.68 | 18.78 | 15.1 | 17.49 | Upgrade
|
| Net Income | 61.19 | -6.38 | 34.76 | 50.26 | 52.47 | Upgrade
|
| Net Income to Common | 61.19 | -6.38 | 34.76 | 50.26 | 52.47 | Upgrade
|
| Net Income Growth | - | - | -30.83% | -4.22% | 8.62% | Upgrade
|
| Shares Outstanding (Basic) | 3 | 3 | 3 | 3 | 3 | Upgrade
|
| Shares Outstanding (Diluted) | 3 | 3 | 3 | 3 | 3 | Upgrade
|
| EPS (Basic) | 19.61 | -2.05 | 11.14 | 16.11 | 16.82 | Upgrade
|
| EPS (Diluted) | 19.61 | -2.05 | 11.14 | 16.11 | 16.82 | Upgrade
|
| EPS Growth | - | - | -30.83% | -4.22% | 8.62% | Upgrade
|
| Free Cash Flow | 22.6 | 5.06 | 29.15 | 21.12 | 35.69 | Upgrade
|
| Free Cash Flow Per Share | 7.25 | 1.62 | 9.34 | 6.77 | 11.44 | Upgrade
|
| Dividend Per Share | 2.500 | 1.000 | 5.000 | 5.000 | 5.000 | Upgrade
|
| Dividend Growth | 150.00% | -80.00% | - | - | - | Upgrade
|
| Gross Margin | 30.71% | 16.63% | 32.03% | 37.58% | 39.49% | Upgrade
|
| Operating Margin | 20.03% | 3.46% | 16.72% | 23.66% | 26.65% | Upgrade
|
| Profit Margin | 14.53% | -2.07% | 10.76% | 17.93% | 19.47% | Upgrade
|
| Free Cash Flow Margin | 5.37% | 1.64% | 9.02% | 7.54% | 13.24% | Upgrade
|
| EBITDA | 91.28 | 18.29 | 61.84 | 74.58 | 80.41 | Upgrade
|
| EBITDA Margin | 21.67% | 5.93% | 19.14% | 26.61% | 29.83% | Upgrade
|
| D&A For EBITDA | 6.92 | 7.62 | 7.82 | 8.25 | 8.57 | Upgrade
|
| EBIT | 84.36 | 10.66 | 54.02 | 66.33 | 71.84 | Upgrade
|
| EBIT Margin | 20.03% | 3.46% | 16.72% | 23.66% | 26.65% | Upgrade
|
| Effective Tax Rate | 27.64% | 161.99% | 35.07% | 23.10% | 25.00% | Upgrade
|
| Advertising Expenses | 0.75 | 0.89 | 0.97 | 0.96 | 0.8 | Upgrade
|
Updated Jan 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.